Literature DB >> 6228193

Comparative activities of norfloxacin and fifteen other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa strains.

K R Forward, G K Harding, G J Gray, B A Urias, A R Ronald.   

Abstract

We compared the activity of norfloxacin (MK-0366), a new orally absorbable derivative of naladixic acid, with those of other antipseudomonal agents against Pseudomonas aeruginosa. Norfloxacin was the most active against both gentamicin-susceptible and gentamicin-resistant strains, having 90% minimal inhibitory concentrations of 2 and 8 micrograms/ml, respectively. This excellent in vitro activity may make norfloxacin effective for oral therapy of P. aeruginosa urinary tract infections.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6228193      PMCID: PMC185382          DOI: 10.1128/AAC.24.4.602

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Norfloxacin and the antibacterial gamma pyridone beta carboxylic acids.

Authors:  S W Newsom; J Matthews; M Amphlett; R E Warren
Journal:  J Antimicrob Chemother       Date:  1982-07       Impact factor: 5.790

2.  Carbenicillin resistance in Pseudomonas aeruginosa from clinical material.

Authors:  J H Darrell; P M Waterworth
Journal:  Br Med J       Date:  1969-07-19

3.  Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates.

Authors:  M Y Khan; R P Gruninger; S M Nelson; R E Klicker
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

4.  In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa.

Authors:  J Downs; V T Andriole; J L Ryan
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

5.  Antibacterial activity of norfloxacin.

Authors:  S R Norrby; M Jonsson
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

6.  Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography.

Authors:  V K Boppana; B N Swanson
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

  6 in total
  7 in total

Review 1.  Antimicrobial agent therapy for Pseudomonas aeruginosa.

Authors:  J A Korvick; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 2.  New insights into the epidemiology, pathogenesis and therapy of Pseudomonas aeruginosa infections.

Authors:  S J Cryz
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

3.  In vitro susceptibilities of 393 recent clinical isolates to WIN 49375, cefotaxime, tobramycin, and piperacillin.

Authors:  D J Pohlod; L D Saravolatz
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

4.  Norfloxacin and silver norfloxacin in the treatment of Pseudomonas corneal ulcer in the rabbit.

Authors:  R W Darrell; S M Modak; C L Fox
Journal:  Trans Am Ophthalmol Soc       Date:  1984

5.  Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.

Authors:  J B Schiff; G J Small; J E Pennington
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

Review 6.  Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; D M Richards
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

Review 7.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.